Soligenix, Inc. SNGX

Nasdaq · Phase 2 · dermatology · small molecule · EDGAR · Updated Nov 7, 2026

Soligenix, Inc. (Nasdaq: SNGX) is a dermatology drug developer. Its lead program, SGX302, is in Phase 2 for Mild-to-Moderate Psoriasis.

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

Program	Indication	Modality	Stage
SGX942	Oral Mucositis in Head and Neck Cancer	protein/peptide	Phase 3
SGX302	Mild-to-Moderate Psoriasis	small molecule	Phase 2
SGX945	Aphthous Ulcers in Behçet's Disease	protein/peptide	Phase 2
RiVax	Ricin Toxin Poisoning	vaccine	Phase 1
ThermoVax (filovirus vaccines)	EBOV, SUDV, BDBV, MARV	vaccine	Pre-clinical

Apr 28, 2026
missed Phase 3 FLASH2 interim efficacy analysis: Data Monitoring Committee recommended halting the study for futility; no HyBryte signal seen at 18 weeks.Under the terms of the interim analysis, the study was recommended to halt for futility. Filing
Feb 12, 2026
positive Open-label investigator-initiated study: 75% of patients achieved Treatment Success after 18 weeks, with 3 of 8 evaluable patients achieving a complete response.Following 18 weeks of continuous “real world” treatment, 75% of patients achieved “Treatment Success,” with three of the eight evaluable patients achieving a complete response over the course of the study. Filing

Cash runway against each catalyst, with the company's own runway statement
Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
Expected move for each dated catalyst, from comparable past events
Phase 2 evidence behind each Phase 3 readout
Companies on the same target or class
Full catalyst list with filing sentences, deals, registered trials, Excel export